Why some bacteria survive antibiotics
Antibiotics are among medicine’s most important tools, but bacteria can evolve ways to defeat them. This guide explains how bacteria differ, which drug-resistant bacteria matter most in wounds and hospitals, how resistance develops and spreads, and why treatment sometimes fails.

Why some bacteria survive antibiotics
1. Two kinds of bacteria: Gram-positive vs gram-negative
In 1884 Hans Christian Gram developed a stain that still sorts bacteria into two big groups. Gram-positive bacteria stain purple; gram-negative bacteria stain pink. The difference comes from how their outer layers, the cell envelope, are built. [7]
-
Gram-positive: No outer membrane, but surrounded by peptidoglycan many times thicker than in gram-negative bacteria. [8] Examples: Staphylococcus aureus (including MRSA) and Enterococcus.
-
Gram-negative: Three layers: an outer membrane studded with lipopolysaccharide (LPS) and porin channels, a thin peptidoglycan wall, and an inner membrane. [7] Examples: Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae.
Why gram-negative bacteria are harder to treat
The outer membrane gives gram-negative bacteria a head start against many drugs.
-
An extra barrier. The outer membrane is the main reason gram-negative bacteria resist many antibiotics. Most drugs must cross it to reach their targets, and gram-positive bacteria lack this layer. [7]
-
Narrow entryways. Some drugs enter only through porin channels. Changing or reducing porins can keep drugs out; some drugs, such as vancomycin, cannot cross the outer membrane at all. [7, 1]
-
Pumps and enzymes. Gram-negative bacteria can use all four main resistance mechanisms, while gram-positive bacteria less often rely on limiting drug uptake. [9] WHO notes they can also pass resistance genes to other bacteria. [6]
Gram-positive bacteria are not harmless: MRSA and vancomycin-resistant Enterococcus (VRE) are both on CDC’s list of serious threats. [3]
2. Key pathogens: The ESKAPE pathogens and wounds
Researchers group six hospital pathogens under the acronym ESKAPE: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species. Their resistance genes have reduced treatment options for serious infections. [11]
-
Staphylococcus aureus / MRSA (Gram +): Broken skin, such as scrapes or cuts, is often the site of a MRSA infection. [12] WHO high priority (methicillin-resistant). [6]
-
Enterococcus / VRE (Gram +): Normally lives in the gut; most VRE infections occur in hospitals, and people who have had surgery are at higher risk. [13] WHO high priority (E. faecium, vancomycin-resistant). [6]
-
Klebsiella pneumoniae (Gram −): Can make carbapenemases, enzymes that break down carbapenems and most other beta-lactam drugs. [1] Among the leading drug-resistant gram-negative bacteria in bloodstream infections. [5]
-
Acinetobacter baumannii (Gram −): Can infect the blood, urinary tract, lungs or wounds, and many strains resist multiple antibiotics. [15] WHO critical priority (carbapenem-resistant). [6]
-
Pseudomonas aeruginosa (Gram −): Patients with open wounds from surgery or burns are at higher risk; some strains resist nearly all antibiotics. [14] WHO high priority (carbapenem-resistant). [6]
-
Enterobacter and other Enterobacterales (Gram −): Carbapenem-resistant Enterobacterales (CRE) are one of CDC’s four urgent threats. [3] WHO lists carbapenem- and third-generation cephalosporin-resistant Enterobacterales as critical. [6]
WHO’s 2024 Bacterial Priority Pathogens List covers 15 families of antibiotic-resistant bacteria in critical, high and medium groups. [6]
Key stats
-
9.3M+ drug-resistant infections in the U.S. each year, with more than 39,000 deaths (bacteria and fungi; 2023 data) [1]
-
1 in 6 laboratory-confirmed bacterial infections worldwide were resistant to antibiotics in 2023 [5]
-
4.7M+ deaths worldwide were associated with bacterial antimicrobial resistance in 2021 [5]
3. How resistance develops and spreads
Resistance is a natural process, but antibiotic use speeds it up by pressuring bacteria to adapt. [1] Bacteria adapt in two main ways: mutations in their own genes, and picking up resistance genes from other bacteria (horizontal gene transfer). [10]

-
Variation. A random mutation, or a gene picked up from another microbe, gives one cell a way to survive a drug. [10]
-
Selection. The antibiotic kills susceptible bacteria. Resistant cells survive. [1]
-
Multiply. Survivors multiply, and their offspring inherit the resistance. [9]
-
Spread. Resistance genes on plasmids can pass to other bacteria, even ones never exposed to the drug. [10, 1]
Four ways bacteria gain resistance
-
Mutation: Changes in genes for drug targets, drug transporters and drug-modifying enzymes. [9]
-
Conjugation: Cell-to-cell transfer, often of plasmids. It is efficient and common when resistance emerges in hospitals. [10]
-
Transformation: Bacteria take up free (“naked”) DNA from their surroundings. [10]
-
Transduction: Viruses that infect bacteria (phages) carry genes between cells. [10]
What speeds it up
-
Overuse and misuse: WHO calls the misuse and overuse of antibiotics, such as taking them when they are not needed or taking the wrong type, one of the main drivers of resistance. [5]
-
Unnecessary prescriptions: In the U.S., at least 30% of antibiotic use is unnecessary. In doctors’ offices, about 1 in 3 antibiotic prescriptions (47 million a year) is unnecessary. [4]
-
Spread between people and places: Resistant germs spread in healthcare facilities, communities, food and the environment, and through travel. [4]
-
Rising resistance: Between 2018 and 2023, resistance rose in more than 40% of the pathogen–antibiotic combinations WHO monitors. [5]
4. Why antibiotics fail
Bacteria defeat antibiotics in four main ways. [9] CDC gives real-world examples of each. [1]
-
Keep the drug out: Gram-negative bacteria can use their outer membrane to stop drugs from entering. [1]
-
Pump it out: Efflux pumps throw drugs out. Some P. aeruginosa pumps remove several antibiotic classes, including fluoroquinolones and beta-lactams. [1]
-
Destroy it: Enzymes break the drug down, like the carbapenemases made by K. pneumoniae. [1]
-
Change the target: The drug’s target changes so the drug no longer fits. For example, the mcr-1 gene helps E. coli resist colistin. [1]
Beyond genetic resistance
-
Tolerance and persisters: Persister cells are a small group that survive intense antibiotic treatment without being genetically resistant, and may contribute to treatment failure. [16]
-
Biofilm: Biofilms resist antibiotics and the immune system, a major cause of persistent and recurring infections. [19] The sticky matrix makes it hard for drugs to reach bacteria. [9] See Biofilm 101 →
-
Too few new drugs: Too few new antibiotics are being developed to replace the ones that no longer work. [5]
From surviving to resisting
Failed or partial treatment can make resistance more likely, not just leave an infection behind.
-
Low or partial exposure → Bacteria are often exposed to drug levels too low to kill them, and those levels can select for resistance. [18]
-
Tolerant survivors → In lab evolution experiments with intermittent antibiotic exposure, tolerance evolved first. In every case, tolerance came before resistance. [17]
-
Resistance takes hold → Tolerance helped resistance mutations spread through the population. [17]
Sources
Pavaka Wound Care is developing a powered wound dressing designed to target biofilm and drug-resistant pathogens. Investigational device; not FDA cleared or approved.
Educational information, not medical advice. This page is general educational content. It does not describe the use or performance of any Pavaka product. If you have a wound or infection, talk with a qualified healthcare professional.
-
CDC. About Antimicrobial Resistance. Updated Oct 25, 2026. https://www.cdc.gov/antimicrobial-resistance/about/index.html
-
CDC. Antimicrobial Resistance Threats Reports (2026 update). Updated Oct 26, 2026. https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html
-
CDC. AR Threats Report 2026: Antimicrobial Resistance Threats (threat list and methods). https://arpsp.cdc.gov/artr/antimicrobial-resistance-threats
-
CDC. Antimicrobial Resistance: Causes and How It Spreads. Sept 25, 2025. https://www.cdc.gov/antimicrobial-resistance/causes/index.html
-
WHO. Antimicrobial resistance (fact sheet). https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
-
WHO. WHO updates list of drug-resistant bacteria most threatening to human health (Bacterial Priority Pathogens List 2024). May 17, 2024. https://www.who.int/news/item/17-05-2024-who-updates-list-of-drug-resistant-bacteria-most-threatening-to-human-health
-
Breijyeh Z, Jubeh B, Karaman R. Resistance of Gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules. 2020;25(6):1340. https://pmc.ncbi.nlm.nih.gov/articles/PMC7144564/
-
Silhavy TJ, Kahne D, Walker S. The bacterial cell envelope. Cold Spring Harb Perspect Biol. 2010;2(5):a000414. https://pmc.ncbi.nlm.nih.gov/articles/PMC2857177/
-
Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018;4(3):482–501. https://pmc.ncbi.nlm.nih.gov/articles/PMC6604941/
-
Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2). https://pmc.ncbi.nlm.nih.gov/articles/PMC4888801/
-
De Oliveira DMP, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33(3):e00181-19. https://pmc.ncbi.nlm.nih.gov/articles/PMC7227449/
-
CDC. Methicillin-resistant Staphylococcus aureus (MRSA) Basics. June 26, 2025. https://www.cdc.gov/mrsa/about/index.html
-
CDC. Vancomycin-resistant Enterococci (VRE) Basics. https://www.cdc.gov/vre/about/index.html
-
CDC. About Pseudomonas aeruginosa. June 12, 2025. https://www.cdc.gov/pseudomonas-aeruginosa/about/index.html
-
CDC. About Acinetobacter. June 12, 2025. https://www.cdc.gov/acinetobacter/about/index.html
-
Balaban NQ, et al. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019;17(7):441–448. https://pubmed.ncbi.nlm.nih.gov/30980069/
-
Levin-Reisman I, et al. Antibiotic tolerance facilitates the evolution of resistance. Science. 2017;355(6327):826–830. https://pubmed.ncbi.nlm.nih.gov/28183996/
-
Andersson DI, Hughes D. Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol. 2014;12(7):465–478. https://pubmed.ncbi.nlm.nih.gov/24861036/
-
Ciofu O, Moser C, Jensen PØ, Høiby N. Tolerance and resistance of microbial biofilms. Nat Rev Microbiol. 2022;20(10):621–635. https://pubmed.ncbi.nlm.nih.gov/35115704/
